NCT05311475 - Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis | Biotech Hunter

Enrollment

669

Participants

Timeline

Start Date

April 4, 2022

Primary Completion Date

June 20, 2023

Study Completion Date

June 20, 2023

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG

Mometasone

Mometasone furoate nasal spray (50 mcg per actuation)

DRUG

Azelastine

Azelastine hydrochloride nasal spray (140 mcg per actuation)

DRUG

Placebo

Placebo nasal spray

Trial Locations (28)

1606

Sandoz Investigative Site, Sofia

Unknown

Sandoz Investigative Site, Burgas

Sandoz Investigative Site, Gabrovo

Sandoz Investigative Site, Plovdiv

Sandoz Investigative Site, Sliven

Sandoz Investigative Site, Sofia

Sandoz Investigative Site, Varna

Sandoz Investigative Site, Aachen

Sandoz Investigative Site, Dreieich

Sandoz Investigative Site, Dresden

Sandoz Investigative Site, Duisburg

Sandoz Investigative Site, Hamburg

Sandoz Investigative Site, Heidelberg

Sandoz Investigative Site, Neuenhagen

Sandoz Investigative Site, Röthenbach

Sandoz Investigative Site, Schorndorf

Sandoz Investigative Site, Viernheim

Sandoz Investigative Site, Chisinau

Sandoz Investigative Site, Brzeg Dolny

Sandoz Investigative Site, Chodzież

Sandoz Investigative Site, Inowrocław

Sandoz Investigative Site, Jaksice

Sandoz Investigative Site, Lodz

Sandoz Investigative Site, Lublin

Sandoz Investigative Site, Ostrowiec

Sandoz Investigative Site, Poznan

Sandoz Investigative Site, Warsaw

Sandoz Investigative Site, Wroclaw